Furthermore, our findings revealed that PSPC protected against NLRP3 inflammasome-mediated inflammation via ameliorating oxidative stress-mediated NAD+ loss and consequent ER stress in the HFD-treated mouse livers, indicating that PSPC is a candidate for pharmacological intervention of obesity-related metabolic diseases. The gene discussed is NLRP3; the disease is obesity due to melanocortin 4 receptor deficiency.